PIIND

Faces Margin Erosion Amid Pyroxasulfone Price Decline

. reported a weak Q3FY26 performance, with consolidated revenue falling to ₹1,376 crore, sharply missing consensus estimates of ₹1,770 crore. The company’s core custom synthesis and manufacturing (CSM) business, contributing over 70% of revenues, declined for the fourth consecutive quarter due to cautious customer ordering and soft product prices. Margins contracted significantly, while diversification efforts into biologicals, pharma CDMO, and electronic chemicals remain at an early stage. Analysts remain cautious, with earnings estimates cut and valuations appearing stretched. Financial & Operating Performance - Revenue: ₹1,376 crore, below consensus estimate of ₹1,770 crore. - CSM business: Fourth straight YoY decline, weak volumes amid cautious customer demand. - EBITDA margin: 22%, down ~500 bps YoY. - FY26 margin guidance: Maintained at 25–26%, despite near-term pressures. Key Challenges - Kumiai Chemicals (major customer) cut FY26 guidance due to pricing pressure and muted herbicide demand. - Pyroxasulfone prices down ~18% YoY to $69/kg, adding margin stress. - Threat of generics in US market and weak ex-pyroxasulfone portfolio growth over past 5–6 years. - JM Financial cut FY26–28 EPS estimates by 16–18%, citing weak revenue visibility. Diversification Strategy - Five new molecules commercialized in 9MFY26, but insufficient to offset pyroxasulfone declines. - Investments in biologicals, pharma CDMO, and electronic chemicals underway, but still nascent. - Long-term diversification aimed at reducing dependence on agrochemicals. Valuation & Outlook - Stock down 18% in past six months, reflecting weak momentum. - Trades at 30x FY27E P/E, considered unattractive given earnings risks. - Recovery hinges on sustained improvement in CSM demand, expected only from FY27. - Near-term outlook remains challenging, with tariff impact, weak demand, and margin pressure likely to persist.